Alnylam Pharmaceuticals, Inc. (ALNY) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulatio...
Alnylam Pharmaceuticals, Inc. (ALNY) currently trades at a P/E ratio of 56.44 (historical range: 49.21–1512.57, median: 981.14), placing it at the 7th percentile — cheap relative to its history, P/S ratio of 7.60 (range: 6.63–25.49, 3th percentile — cheap relative to its history).
Alnylam Pharmaceuticals, Inc. appears significantly undervalued relative to its historical range, trading at depressed multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 56.44 | 49.21 | 981.14 | 1512.57 | 7th | cheap relative to its history |
| P/S Ratio | 7.60 | 6.63 | 15.24 | 25.49 | 3th | cheap relative to its history |
| FCF Yield | 0.00 | 0.00 | 0.00 | 0.01 | 46th | near its historical average |